Everything below concerns reversed-phase chromatography. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
=== Procedure in the United States === In the United States, the typical lethal injection begins with the condemned person being strapped onto a gurney; two IV cannulas are then inserted, one in each arm. Only one is necessary to carry out the execution; the other is reserved as a backup in the event the primary line fails. A line leading from the IV line in an adjacent room is attached to the prisoner's IV and secured so that the line does not snap during the injections. The arm of the condemned person is swabbed with alcohol before the cannula is inserted. The needles and equipment used are sterilized. Although the person is not expected to survive the injection, there are nonetheless reasons to use measures against infection. First, sterile equipment is mass-produced and readily available from medical suppliers. Secondly, the prisoner could receive a stay of execution after the cannulae have been inserted, as in the case of James Autry in October 1983. Third, the use of unsterilized equipment would be a hazard to the prison personnel in case of an accidental needle stick injury. Following the connection of the lines, saline drips are started in both arms. This, too, is standard medical procedure: it must be ascertained that the IV lines are clear, ensuring the chemicals have not precipitated in them and blocked the needle, preventing the drugs from reaching the subject. A heart monitor is attached to the inmate.
=== Hematopoietic stem cell transplantation === Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for both alpha and beta thalassemia. It involves replacing the dysfunctional stem cells in the bone marrow with healthy cells from a well-matched donor. Cells are ideally sourced from human leukocyte antigen matched relatives; the procedure is more likely to succeed in children rather than adults. The first HSC transplant for thalassemia was carried out in 1981 on a patient with beta thalassemia major. Since then, a number of patients have received bone marrow transplants from healthy matched donors, although this procedure has a high level of risk. In 2018 an unborn child with hydrops fetalis, a potentially fatal complication of alpha thalassemia, was successfully transfused in utero with her mother's stem cells. HSCT is a dangerous procedure with many possible complications; it is reserved for patients with life-threatening diseases. Risks associated with HSCT can include graft-versus host disease, failure of the graft, and other toxicity related to the transplant. In one study of 31 people, the procedure was successful for 22 whose hemoglobin levels improved to the normal range, in seven the graft failed and they continued to live with thalassemia, and two died of transplantation-related causes.
=== The beginnings of the Rowett Research Institute === On 1 April 1914, Boyd Orr took charge of a new research institute in Aberdeen, a project of a joint committee for research into animal nutrition of the North of Scotland College of Agriculture and the University of Aberdeen. He had been offered the post on the recommendation of E. P. Cathcart, who had originally been offered the job, but had turned it down in favour of a chair in physiology in London. The joint committee had allocated a budget of £5,000 for capital expenditure and £1,500 for annual running costs. Boyd Orr recognised immediately that these sums were inadequate. Using his experience in his father's business of drawing up plans and estimating costs, he submitted a budget of £50,000 for capital expenditure and £5,000 for annual running costs. Meanwhile, with the £5,000 he had already been allocated he specified a building, not of wood as had been envisaged by the committee, but of granite and designed so that it could serve as a wing of his proposed £50,000 Institute. He accepted the lowest tender of £5,030, and told the contractors to begin work immediately. The committee were not pleased, but had to accept the fait accompli. When war broke out the contractors were told to finish the walls and roof, but to do no more for the time being.
On 7 April (8 April in Iran and Israel), Trump announced that he agreed to a two-week ceasefire with Iran and the proposal by Pakistan, stating that Iran would immediately open the Strait of Hormuz and work on finalizing a peace agreement. Later on the same day, Abbas Araghchi announced that Iran had agreed to the conditions. Iran claimed victory, asserting that it had forced the US to accept its 10-point plan, which includes lifting all sanctions on Iran and withdrawing all US forces from all bases in the region. Trump said the Iranian 10 point proposal was a "workable basis on which to negotiate". Hezbollah announced a pause in attacks against Israel, according to the ceasefire. Israel has also agreed to the temporary ceasefire. According to Pakistani Prime Minister Shehbaz Sharif, the ceasefire includes all fronts of the war, including Lebanon. Israeli Prime Minister Benjamin Netanyahu rejected Sharif's inclusion of Lebanon, asserting that the ceasefire "does not include Lebanon", an assertion backed by Trump and Vance. Hezbollah said that it halted attacks on Israel and on Israeli soldiers in Lebanon. A few hours later Israel launched the strongest wave of attacks on Lebanon since the start of the war. In response, Iranian media later said that Iran paused Hormuz traffic over Israeli attacks in Lebanon. The Lebanese government denounced what occurred as a war crime. The IRGC warned of a 'regretful response' if the attacks on Lebanon do not stop.
Sources: en.wikipedia.org
== Background == Folin was born in Åseda, Småland in Sweden. He was the seventh of twelve children of Nils Magnus Folin and Eva Olson. He moved to America at the age of fifteen following two brothers and an aunt who had already settled there. He carried on his schooling in Stillwater, Minnesota. He moved to Minneapolis, Minnesota entering the University of Minnesota and completed his B.S in 1892.
In the United States and Canada, cottage cheese is used in many culinary dishes. It can be combined with fruit and sugar, salt and pepper, fruit purée, tomatoes, or granola and cinnamon. It can be eaten on toast, in salads, as a chip dip, as a replacement for mayonnaise in tuna salad, and as an ingredient in recipes such as jello salad and various desserts. Cottage cheese is also consumed with fruit, such as pineapple, pears, peaches, or mandarin oranges. The sour taste of the product is due to lactic acid, which is present at 124–452 mg/kg. Formic, acetic, propionic and butyric acids contribute to the flavor and aroma. Due to its incorporation of whey, cottage cheese is high in lactose relative to most other cheeses. However, lactose is partially decomposed by lactic acid fermentation, and is mostly removed after washing the curds.
=== Parallel MRI === It takes time to gather MRI data using sequential applications of magnetic field gradients. Even for the most streamlined of MRI sequences, there are physical and physiologic limits to the rate of gradient switching. Parallel MRI circumvents these limits by gathering some portion of the data simultaneously, rather than in a traditional sequential fashion. This is accomplished using arrays of radiofrequency (RF) detector coils, each with a different 'view' of the body. A reduced set of gradient steps is applied, and the remaining spatial information is filled in by combining signals from various coils, based on their known spatial sensitivity patterns. The resulting acceleration is limited by the number of coils and by the signal to noise ratio (which decreases with increasing acceleration), but two- to four-fold accelerations may commonly be achieved with suitable coil array configurations, and substantially higher accelerations have been demonstrated with specialized coil arrays. Parallel MRI may be used with most MRI sequences. After a number of early suggestions for using arrays of detectors to accelerate imaging went largely unremarked in the MRI field, parallel imaging saw widespread development and application following the introduction of the simultaneous acquisition of spatial harmonics (SMASH) technique in 1996–7. The sensitivity encoding (SENSE) and generalized autocalibrating partially parallel acquisitions (GRAPPA) techniques are the parallel imaging methods in most common use today.
Following the country's independence as Zimbabwe, Towsey became chargé d'affaires at the new embassy. The High Commission in London, known as Rhodesia House, continued to function until it was closed in 1969 following the decision by white Rhodesians in a referendum to make the country a republic, along with the "British Residual Mission" in Salisbury. Prior to its closure, the mission flew the newly adopted Flag of Rhodesia, considered illegal by the Foreign Office, prompting calls by Labour MP Willie Hamilton for its removal. In Australia, the federal government sought to close the Rhodesia Information Centre in Sydney, but it remained open, operating under the jurisdiction of the state of New South Wales. In 1973, the Labor government of Gough Whitlam cut post and telephone links to the centre, but this was ruled illegal by the High Court. An office was also established in Paris, but this was closed down by the French government in 1977. Similarly, the United States recalled its consul-general from Salisbury, and reduced consular staff, but did not move to close its consulate until the declaration of a republic in 1970. South Africa, however, retained its "Accredited Diplomatic Representative" after UDI, which allowed it to continue to recognise British sovereignty as well as to deal with the de facto authority of the government of Ian Smith. The South African Diplomatic Mission in Salisbury became the only such mission remaining in the country after 1975, when Portugal downgraded its mission to consul level, having recalled its consul-general in Salisbury in May 1970.
==== MeSH D12.776.624.664.500 – oncogene proteins, fusion ==== MeSH D12.776.624.664.500.100 – fusion proteins, bcr-abl MeSH D12.776.624.664.500.320 – fusion proteins, gag-onc MeSH D12.776.624.664.500.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.624.664.500.660 – oncogene protein tpr-met
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.